PMS50 Benefits in Patient Reported Outcomes Supporting a “Treat to Target” Paradigm for Infliximab -Treated RA Patients Previously Inadequately Responsive to Prior Anti-TNF Treatment
Abstract
Authors
M. Ingham L. Tang D. Decktor R. Bolce J. Wang